Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetes.

BACKGROUND: The objective was to compare the effects on glycemia of adding either inhaled human insulin (Exubera [EXU] [insulin human (recombinant DNA origin) inhalational powder]) or subcutaneous insulin glargine (GLA) to the treatment regimens of patients with type 2 diabetes uncontrolled with oral antidiabetic drugs. METHODS: Forty patients were randomized to receive either EXU three times daily prior to meals or subcutaneous GLA once daily in a crossover design. Interstitial glucose concentrations were monitored using a continuous glucose monitoring system (CGMS) for the final 72-h period of 8 treatment days. RESULTS: Total insulin dosage on the last treatment day was approximately 40.1+/-18.1 units/day EXU compared with 16.4+/-4.8 units/day GLA. Serum insulin levels over the 72-h CGMS period were higher for EXU than for GLA (1,091+/-589 pmol/mL/h vs. 737+/-386 pmol/mL/h; ratio, 148; 95% confidence interval [CI], 130-169). The glucose exposure over this period was lower with EXU than with GLA (380+/-45 mmol/Lh vs. 426+/-89 mmol/Lh; ratio, 88.57; 95% CI, 84-93). The overall hypoglycemic event rate was 8.7 events per subject-month for EXU and 2.4 for GLA. CONCLUSIONS: Prandial insulin therapy with EXU, using a higher daily insulin dose, reduces total daily glucose exposure--in particular postmeal glycemia--more effectively than a basal insulin analog.